medigraphic.com

2007, Número 2

<< Anterior Siguiente >>

Arch Cardiol Mex 2007; 77 (2)


Reestenosis clínica en pacientes diabéticos con implante de stents liberadores de fármaco en lesiones de novo

Palomo VJA, Bernal E, Santiago J, Abundes VA, Montoya SA, Flores FJ, González DB, Astudillo SR, Estrada GJ, Farell CJ

Idioma: Español
Referencias bibliográficas: 58
Paginas: 110-119
Archivo PDF: 127.02 Kb.


RESUMEN

Revisamos la colocación de endoprótesis vasculares “stents” medicados y evaluamos los resultados clínicos y angiográficos, así como el seguimiento de los pacientes diabéticos que fueron sometidos a intervención coronaria percutánea (ICP). Material y métodos: En el período comprendido del 1 de noviembre de 2004 al 31 de junio del 2005 durante el cual se realizaron 860 procedimientos de cardiología intervencionista, con aplicación de 112 stents medicados, de éstos a 42 pacientes con diagnóstico de diabetes mellitus (DM) con (2.6 stents por paciente), de tipo paclitaxel 60% y con sirolimus 40% con edades de 58 a 76 años promedio de 51.2 ± 9.6 de sexo masculino 25 (60%) y femenino 17 (40%). Con angina inestable 15 (35%) y angina estable 27 (65%) según la Canadian Cardiovascular Society (CCS). Con antecedentes de infarto del miocardio antiguo de localización anterior 20 (47%) inferior 8 (20%) y con enfermedad de múltiples vasos 16 (38%). El porcentaje promedio de obstrucción vascular fue de 85.9 ± 12.2 y la fracción de expulsión en rangos de 45 a 65 promedio (55 ± 10). Tiempo promedio de hospitalización 7 ± 5.4 días. Resultados: El éxito clínico y angiográfico inmediato fue del 100%, el seguimiento clínico promedio fue de 7.6 ± 3.3 meses en 34 (80.9%) del total de los casos, sólo con revascularización de la lesión tratada (RLT) en 3 (7.1%). No reportamos eventos cardíacos adversos mayores: muerte, infarto o reinfarto (0%). Complicaciones: un paciente (2.3%) con insuficiencia renal aguda asociada al medio de contraste. Conclusiones: Estos resultados sugieren que la aplicación de stents medicados (paclitaxel o sirolimus) en DM es un procedimiento exitoso clínico y angiográfico con bajo porcentaje de complicaciones y reestenosis a pesar de su mayor perfil de riesgo.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Escobedo de la Peña J: Frecuencia de la diabetes mellitus, mortalidad y morbilidad. Temas de Medicina Interna: Interamericana. Asociación de Medicina Interna de México; 1993; 4(1): 643-653.

  2. Instituto Nacional de Nutrición Salvador Zubirán: Encuesta Nacional de Enfermedades Crónicas: Dirección General de Epidemiología; 1993.

  3. Hamby R, Sherman L, Metha J, Aintablian A: Repraisal of the role of diabetic state in coronary artery disease. Chest 1976; 70: 251-257.

  4. Esmatjes E, Vidal J: Repercución cardíaca de la diabetes mellitus. Rev Esp Cardiol 1998; 51(8): 661-670.

  5. Dortimer A, Shenoy P, Shiroff R, Leaman D, Babb J, Liedtke A, et al: Diffuse coronary artery disease in diabetic patients: fact or fiction? Circulation 1978; 57: 133-136.

  6. Kannel W, McGee D: Diabetes and cardiovascular disease: the Framingham Study. JAMA 1979; 241: 2035-2038.

  7. Uusitupa M, Niskanen L, Siitonen O, Voutilainen E, Pyorala K: 5 year incidence of atherosclerotic vascular disease in relation in general risk factor, insulin level and abnormalities in lipoprotein composition in non- insulin-dependent diabetic and no diabetic subjects. Circulation 1990; 82: 27-36.

  8. Krolewiski A, Kozinki E, Warram J, Leland O, Busick E, Asmal A, et al: Magnitude and determinants of coronary artery disease in juvenile onset insulin-dependent diabetes mellitus. Am J Cardiol 1987; 59: 750-755.

  9. Stamler J, Vaccaro O, Neaton J, Wenworth D, for the Multiple Risk Factor Interventional Trial Research Group: Diabetes, other risk factors and 12 year cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care 1993; 16: 434-444.

  10. Van B, Bauters C, Hubert R, Bodart J, Abolmaali K, Meurice T: Restenosis rates in diabetic patients: a comparison of coronary stenting and balloon angioplasty in native coronary arteries. Circulation 1997: 96; 1454-1460.

  11. Serruys P, De Jaeguer P, Kiemenei F: A comparison of balloon-expandable–stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.

  12. Berger P, Bell M, Grill D, Melby S, Holmes D: Frequency of adverse clinical events in the 12 following successful intracoronary stent placement in patient treated with aspirin and ticlopidina. Am J Cardiol 1999; 81: 713-718.

  13. Mousa I, Oetgen M, Roubin G, Colombo A, Wang X: Effectiveness of Clopidogrel and aspirin versus ticlopidina and aspirin in preventing stent thrombosis after coronary stent implantation. Circulation 1999; 18: 2364-2366.

  14. Kleinman N, Lincoff A, Kereiakes D, Millier D, Aguirre F: Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin. Evidence for a complex interaction in metacenters. Circulation 1998; 97: 1912-1920.

  15. Stein B, Weintraub W, Gebhart S, Cohen C, Grosswald R, Liberman H, et al: Influence of diabetes mellitus on early and late outcome after percutaneous Transluminal Coronary Angioplasty. Circulation 1995; 91: 979-989.

  16. Savage M, Fishman D, Slota P, Rake R, Leon M, Schatz R: Coronary intervention in the diabetic patient: improved outcome following stent implantation versus balloon angioplasty. J Am Coll Cardiol 1997; 29(Suppl A): 188A.

  17. Carroza J, Kuntz R, Fishman R, Baim D: Restenosis after arterial injury caused by coronary stenting in patients with diabetes mellitus. Ann Inter Med 1993; 118: 344-349.

  18. Elezi S, Schulen H, Wehinger A, Zitzmann-Roth E, Walter H, Hausleiter J: Stent placement in diabetic versus non diabetic, six month angiographic follow-up. J Am Coll Cardiol 1997; 29(Suppl A): 118.

  19. Yokoi H, Nosaka H, Kimura T, Tamura T, Nakagawa Y, Hamasaki N, et al: Coronary stenting in the diabetic patients: early and follow-up results. J Am Coll Cardiol 1997; 27(Suppl A): 455A.

  20. Abizaid A, Mehran R, Bucher T, Greenberg A, Popma J, Mintz G, et al: Does diabetics influence clinical recurrence after coronary stent implantation. J Am Coll Cardiol 1997; 29(Suppl A): 188A.

  21. Elezi S, Kastrati A, Pache J, Wehinger A, Hadamitzky M, Dirschinger J, et al: Diabetes mellitus and the clinical and angiographic outcome after coronary stent placement. J Am Coll Cardiol 1998; 32: 1866-1873.

  22. Ortolani P, Ardissino D, Cavallini C, Bramucci E, Indolfi C, Aquilina M, et al: Effect of Sirolimus-Eluting Stent in Diabetic Patients with Small Coronary Arteries (A SES-SMART Substudy). Am J Cardiol 2005; 96: 1393-98.

  23. Hermiller J, Raizner A, Cannon L, Gurbel P, Kutcher M, Chiu S, et al: Outcomes with the polymer-based paclitaxel-eluting TAXUS stent in patients with diabetes mellitus. The TAXUS-IV trial. J Am Coll Cardiol 2005; 45: 1172-79.

  24. Hammoud J Tanguay J, Bourassa M: Management of coronary artery disease: therapeutic options in patients with Diabetes. J Am Coll Cardiol 2000; 36: 355–65.

  25. Souza J, Costa M, Abizaid A, Renzing B, Abizaid A, Tanajura L, et al: Sustained suppression of neointimal proliferation by sirolimus-eluting stents. One year angiographic and intravascular ultrasound follow-up. Circulation 2001; 104: 2007-2011.

  26. Morice M, Serruys P, Sousa E, Fajadet J, Ban Hayashi E, Perin M, et al: A randomized of sirolimus-eluting stent with a standard stent for coronary revascularization. N Engl J Med: 2002; 346: 1773-1789.

  27. Ledesma M, Farell J, Astudillo R, Abundes A, Escudero J, Montoya A: Stents coronarios: Experiencia en el Hospital de Cardiología del Centro Médico Siglo XXI. Arch Inst Cardiol Mex 1997; 67: 101-105.

  28. Palomo J, Solorio S, Farell J, Abundes A, Ledesma M: Resultados inmediatos post implante de stents coronarios en pacientes octogenarios. Arch Inst Cardiol Mex 1999; 68: 18-26.

  29. Martinez RM, Elid G, Luna J, Villavicencio R, Ban E, Gaspar J, et al: Beneficio del stent coronario en la reducción de complicaciones cardíacas mayores en síndromes coronarios agudos. Arch Inst Cardiol Mex 1999; 69: 121-126.

  30. Farell J, Palomo J, Abundes A, Ledesma M: Stent en tronco coronario izquierdo protegido y no protegido: Resultados y seguimiento a corto plazo. Arch Inst Cardiol Mex 2000; 70: 38-45.

  31. Palomo J, Reyes F, Plaza A, Farell J, Abundes A, Montoya A, et al: Seguimiento clínico y angiográfico en adultos jóvenes post ACTP más stents intracoronarios. Arch Cardiol Mex 2001; 71: 34-42.

  32. Palomo J, Reyes F, Montoya A, Farell J, Abundes A, Ledesma M: Resultados inmediatos y a mediano plazo post implante de stents coronarios en pacientes diabéticos. Arch Cardiol Mex 2002; 72: 36-44.

  33. Palomo J, Padilla F, Reyes F, Montoya A, Astudillo R, Flores J, Farell J, et al: Resultados de implantación de stent coronario en angioplastía primaria en el infarto agudo del miocardio. Rev Mex Cardiol 2004; 15(2): 66-74.

  34. Mock M, Colmes D, Vliestra R, Gersh B, Detret K, Kelsey N, et al: Percutaneous transluminal coronary angioplasty (PTCA) in the elderly patients: experience in the National Heart, Lung and Blood Institute PTCA Registry. Am J Cardiol 1984; 53: 89C-91C.

  35. Ryan T, Bauman W, Kennedy J, Kereiakes D, King III S, McCallister B, et al: Guidelines for percutaneous transluminal coronary angioplasty. A report of the American College of Cardiology/American Heart Association task force on assessment of diagnostic and therapeutic cardiovascular procedures (Committee on percutaneous transluminal coronary angioplasty). J Am Coll Cardiol 1993; 22: 2033-2054.

  36. Feed M, O´Neill V, Safian R: Dissection and acute closure. The manual of Interventional Cardiology. Birmingham, Michigan. Physician’s Press 2000: 387-405.

  37. Fishman D, Leon M, Baim D: A randomized comparison of coronary stent placement and balloon angioplasty in the treatment of coronary artery disease. N Engl J Med 1994; 331: 496-501.

  38. Serruys P, Jaegere P, Kiemeneij F: A comparison of balloon expandable stent implantation with balloon angioplasty in patients with coronary artery disease. N Engl J Med 1994; 331: 489-495.

  39. Rodriguez A, Santaera O, Larribau M: Coronary stenting decreases restenosis in lesions with early loss in luminal diameter 24 hours after successful PTCA. Circulation 1995; 91: 1397-1402.

  40. Grube E, Silber S, Hauptmann K, Mueller R, Buellesfeld L, Gerckens U, et al: TAXUS I. Six and twelve-months results from randomized, double-blind trial on a slow-release Paclitaxel-eluting stent for De Novo coronary lesions. Circulation 2003; 107: 38-42.

  41. Tanabe K, Serruys P, Grube E, Smits P, Selbach G, Van der Giessen W, et al: TAXUS III Trial. In stent restenosis treated with stent based delivery of paclitaxel incorporated in a slow-release polymer formulation. Circulation 2003; 107: 559-564.

  42. Regar E, Serruys P, Bode C, Holubarsch C, Germonprez J, Wijns W, et al: Angiographic findings of the multicenter randomized study with the Sirolimus-eluting Bx Velocity balloon-expandable stent (RAVEL). Circulation 2002; 106: 1949-1956.

  43. Smith S, Faxon D, Cascio W, Schaff H, Gardner T, Jacobs A, et al: Prevention Conference VI. Diabetes and Cardiovascular Disease. Revascularization in Diabetes Patients. Circulation 2002; 105: e165- e169.

  44. Yang T, Park S, Hong M, Park D, Park K, Kim Y, et al: Impact of diabetes mellitus on angiographic and clinical outcomes in the drug-eluting stents era. Am J Cardiol 2005; 96: 1389-92.

  45. Schofer J, Schluter M, Gershlick A, Wijns W, Garcia E, Schampaert E, et al: Sirolimus-eluting stents for treatment of patients with long atherosclerotic lesions in small coronary arteries: double-blind randomized controlled trial (E-SIRIUS). Lancet 2003; 362: 1093-1099.

  46. Moses J, Leon M, Popma J, Fitzgerald P, Holmes D, O‘Shaughnessy C, et al: Sirulimus-eluting stents versus standards stents in patients with stenosis in a native coronary artery. ( SIRIUS Investigators). N Engl J Med 2003; 349: 1315-1323.

  47. Schampaert E, Cohen E, Schluter M, Reeves F, Traboulsi M, Title L, et al: The Canadian study of the Sirulimus-eluting stent in the treatment of patients with long De Novo Lesions in small native coronary arteries (C-SIRIUS). J Am Coll Cardiol 2004; 43: 1110-1115.

  48. Ardisisino D, Cavallini C, Bramucci E, Indolfi C, Marzocchi A, Manari A, et al: (SES-MART) Sirulimus-eluting vs uncoated stents for prevention of restenosis in small coronary artery. JAMA 2004; 292: 2727-2734.

  49. Gershlick A, De Scheerder I, Chevalier B, Stephens A, Camenzind E, Vrints C, et al: Inhibition of restenosis with a paclitaxel-eluting, polymer-free coronary stent. The European evaluation of paclitaxel eluting stent. (ELUTES) trial. Circulation 2004; 109: 487-493.

  50. Stone G, Ellis E, Cox D, Hermiller J, O‘Shaughnessy C, Mann C, et al: A polymer- based paclitaxel-eluting stent in patients with coronary artery disease. N Engl J Med 2004; 350: 221-231.

  51. Kastrati A, Mehilli J, Von Beckerth N, Dibra A, Hauslester J, Pache H, et al: Sirulimus-eluting stent or paclitaxel-eluting stent vs balloon angioplasty for prevention of recurrences in patients with coronary in-stent restenosis. JAMA 2005; 293: 165-171.

  52. Hermiller J, Raizner A, Cannon L, Gurbel P, Kutchner M, Wong S, et al: Outcomes with the polymer-based paclitaxel-eluting TAXUS Stent in patients with Diabetes Mellitus. The TAXUS –IV Trial. J Am Coll Cardiol 2005; 45: 1172-1179.

  53. Hong M, Mintz G, Lee Ch, Song J, Ham K, Kang D, et al: Paclitaxel coating reduces in-stent intimal hyperplasia in human coronary arteries. A serial volumetrical intravascular ultrasound analysis from the Asian Paclitaxel–eluting stent clinical trial. (ASPECT). Circulation 2003; 107: 517-520.

  54. Lansky A, Costa R, Mintz G, Tsuchiya Y, Midei M, Cox D, et al: Non Polymer based Paclitaxel-coated coronary stents for the treatment of patients with De Novo coronary lesions. Angiographic follow-up of the DELIVER clinical trial. Circulation 2004; 109: 1948-1954.

  55. Goy J, Stauffer J, Siegenthaler M, Benoit A, Seydoux C: A prospective randomized comparison between paclitaxel and sirolimus stents in the real world of Interventional Cardiology. The TAXI Trial. J Am Coll Cardiol 2005; 45: 308-311.

  56. Babapulle M, Joseph L, Belisle P, Brophy J, Eisenberg M: A hierachial Batesian meta-analysis of randomized clinical trials of drug-eluting stents. Lancet 2004; 364: 583-591.

  57. Windecker S, Remondino A, Eberli F, Juni P, Raber L, Wenaweser P, et al: Sirolimus-eluting and paclitaxel-eluting stents for coronary revascularization. N Engl J Med 2005; 353: 653-662.

  58. Dibra A, Kastrati A, Mehilli J, Pache J, Schuhlen H, Von Beckerath N, et al: ISAR-DIABETES. Paclitaxel-eluting stent or Sirolimus-eluting stents to prevent restenosis in Diabetic patients. N Engl J Med 2005; 353: 663-670.




2020     |     www.medigraphic.com